

Editor Josef S Smolen

Associate Editors

Francis Berenhaum Dimitrios Boumnas Gerd Burmester Mary Crow lain McInnes Thomas Pap David Pisetsky Désirée van der Heijde Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases BMJ Publishing Group Ltd RMA House Tavistock Square London WCIH 9JR, UK +44 (0)20 3655 5889 E: ard@bmj.com Twitter: @ARD_BMJ ISSN: 0003-4967 (print) ISSN: 1468-2060 (online) **Impact Factor:** 12.350

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism owners grant editorial freedom tothe Editor of ARD.
ARD follows guidelines on editorial independence
produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2018 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd. Chennai, India and printed in the UK on acid-free

Annals of the Rheumatic Diseases (ISSN No. 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431 POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Editorial

Contents

1095 Disease activity in ankylosing spondylitis: the global therapeutic target D Wendling, C Prati, J Sieper

Heroes and pillars of rheumatology

1097 Jacques FORESTIER, a visionary of the clinical epidemiology in rheumatology M Dougados

Review

1099 Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis

> S Hilliquin, B Hugues, S Mitrovic, L Gossec, B Fautrel

Clinical and epidemiological research

1107 Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative

T Constantin, I Foeldvari, J Anton, J de Boer, S Czitrom-Guillaume, C Edelsten, R Gepstein, A Heiligenhaus, CA Pilkington, G Simonini, Y Uziel, S J Vastert, N M Wulffraat, A-M Haasnoot, K Walscheid, A Pálinkás, R Pattani, Z Györgyi, R Kozma, V Boom, A Ponyi, A Ravelli, A V Ramanan

1118 Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modelling approach

EJF Santos, C Duarte, RJO Ferreira, A M Pinto, R Geenen, J A P da Silva, On behalf of the 'Promoting Happiness Through Excellence of Care' Group

1125 The use of MRI-detected synovitis to determine the number of involved joints for the 2010 ACR/EULAR classification criteria for Rheumatoid Arthritis – is it of additional benefit?

> A C Boer, D M Boeters, A H M van der Helm-van Mil

1130 ACPA IgG galactosylation associates with disease activity in pregnant patients with rheumatoid arthritis

> A Bondt, L Hafkenscheid, D Falck, T M Kuiiper, Y Rombouts, J M W Hazes, M Wuhrer, R J E M Dolhain


1137 Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis

M Dubreuil, Q Louie-Gao, C E Peloquin, HK Choi, Y Zhang, T Neogi

1143 Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

> P Charles, B Terrier, É Perrodeau, P Cohen, S Faguer, A Huart, M Hamidou, C Agard, B Bonnotte, M Samson, A Karras, N Jourde-Chiche, F Lifermann, P Gobert, C Hanrotel-Saliou, P Godmer, N Martin-Silva, G Pugnet, M Matignon, O Aumaitre, J-F Viallard, F Maurier, N Meaux-Ruault, S Rivière, J Sibilia, X Puéchal, P Ravaud, L Mouthon, L Guillevin, for the French Vasculitis Study Group

1150 Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides



1157 Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire


> J C Robson, J Dawson, H Doll, P F Cronholm, N Milman, K Kellom, S Ashdown, E Easley, D Gebhart, G Lanier, J Mills, J Peck, R A Lugmani, I Shea, G Tomasson, P A Merkel

1165 Comparison of magnetic resonance angiography and ¹⁸F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis K A Quinn, M A Ahlman, A A Malayeri, J Marko, A C Civelek, J S Rosenblum, A A Bagheri, P A Merkel, E Novakovich, P C Grayson

MORE CONTENTS ▶



This article has been chosen by the Editor to be of special interest or importance and is freely available online.



Journals open access scheme. See http://authors.bmj.com/open-access/



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

http://publicationethics.org/





1172 Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study

G Moulis, G Pugnet, N Costedoat-Chalumeau, A Mathian, G Leroux, J Boutémy, O Espitia, L Bouillet, S Berthier, J-B Gaultier, P-Y Jeandel, A Konaté, A Mékinian, E Solau-Gervais, B Terrier, D Wendling, F Andry, C Garnier, P Cathébras, L Arnaud, A Palmaro, P Cacoub, Z Amoura, J-C Piette, P Arlet, M Lapeyre-Mestre, L Sailler

1179 Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer

> T Igusa, L K Hummers, K Visvanathan, C Richardson, F M Wigley, L Casciola-Rosen, A Rosen, A A Shah

1187 Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study S F Keller, N Lu, K G Blumenthal, S K Rai, C Yokose, J W J Choi, S C Kim, Y Zhang, H K Choi

1194 Identification of calcium pyrophosphate deposition disease (CPPD) by ultrasound: reliability of the OMERACT definitions in an extended set of joints—an international multiobserver study by the OMERACT Calcium Pyrophosphate Deposition Disease Ultrasound Subtask Force

G Filippou, C A Scirè, A Adinolfi, N S Damjanov, G Carrara, G A W Bruyn, T Cazenave, M A D'Agostino, A Delle Sedie, V Di Sabatino, M E Diaz Cortes, E Filippucci, F Gandjbakhch, M Gutierrez, D K Maccarter, M Micu, I Möller Parera, G Mouterde, M A Mortada, E Naredo, C Pineda, F Porta, A M Reginato, I Satulu, W A Schmidt, T Serban, L Terslev, V Vlad, F A Vreju, P Zufferey, P Bozios, C Toscano, V Picerno, A Iagnocco

Basic and translational research

1200 Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjögren's syndrome

E K Kapsogeorgou, A Papageorgiou, A D Protogerou, M Voulgarelis, A G Tzioufas

1208 Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts

Y He, P-S Tsou, D Khanna, A H Sawalha

1219 *In vivo* visualisation of different modes of action of biological DMARDs inhibiting osteoclastic bone resorption

Y Matsuura, J Kikuta, Y Kishi, T Hasegawa, D Okuzaki, T Hirano, M Minoshima, K Kikuchi, A Kumanogoh, M Ishii **1226** Metabolic pathways and immunometabolism in rare kidney diseases

P C Grayson, S Eddy, J N Taroni, Y L Lightfoot, L Mariani, H Parikh, M T Lindenmeyer, W Ju, C S Greene, B Godfrey, C D Cohen, J Krischer, M Kretzler, P A Merkel, the Vasculitis Clinical Research Consortium, the European Renal cDNA Bank cohort, and the Nephrotic Syndrome Study Network

Letters

1234 Shared epitope positivity is related to efficacy of abatacept in rheumatoid arthritis K Oryoji, K Yoshida, Y Kashiwado, K Tanaka, S Mizuki, H Tsukamoto, K Kamada, K Akashi

1236 Seropositivity combined with smoking is associated with increased prevalence of periodontitis in patients with rheumatoid arthritis

K Eriksson, L Nise, L Alfredsson, A I Catrina, J Askling, K Lundberg, L Klareskog, T Yucel-Lindberg

1238 Amount of smoking, duration of smoking cessation and their interaction with silica exposure in the risk of rheumatoid arthritis among males: results from the Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study *P Zeng, Z Chen, L Klareskog, L Alfredsson,*

P Zeng, Z Chen, L Klareskog, L Alfredsson, C Bengtsson, X Jiang

1241 High-dose ustekinumab for severe childhood deficiency of interleukin-36 receptor antagonist (DITRA)

N Bonekamp, R Caorsi, G M Viglizzo, M de Graaf, F Minoia, A Grossi, P Picco, I Ceccherini, J Frenkel, M Gattorno

- **1243** Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults *J A Singh, J D Cleveland*
- **1245** 'Twitterland': a brave new world?

 E Nikiphorou, P Studenic, A Alunno, M Canavan,
 M Jani, F Berenbaum

Electronic pages

- Discussion of Methotrexate Dosage S A Maguire, C M Sheehy
- e48 Response to eLetter: 'Discussion of methotrexate dosage' by Maguire et al M Safy, J W G Jacobs, N D Ifff, J W J Bijlsma, J M van Laar, M J H de Hair, Society for Rheumatology Research Utrecht (SRU)
- **e49** Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: an updated meta-analysis

 CM Olsen, A C Green

- e50 Antisynthetase syndrome or what else?

 Different perspectives indicate the need for new classification criteria
 - L Cavagna, S Castañeda, C Sciré, M A Gonzalez-Gay, On Behalf of the AENEAS Collaborative Group Members
- esses to: 'Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria' by Cavagna et al J B Lilleker, J Vencovsky, G Wang, L R Wedderburn, L P Diederichsen, J Schmidt, P Jordan, O Benveniste, M G Danieli, K Dankó, N T Phuong Thuy, M V-D Mercado, H Andersson, B D Paepe, J L De Bleecker, B Maurer, L J McCann, N Pipitone, N McHugh, Z Betteridge, P New, R G Cooper, W E Ollier, J A Lamb, N S Krogh, I E Lundberg, H Chinoy, On behalf of all EuroMyositis contributors
- **e52** Obesity and CRP *F Aslam*
- e53 Response to: the value of 18(F)-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study V Schönau, G Schett
- **e54** Chondroitin sulfate is superior to placebo in symptomatic knee osteoarthritis YHLee
- **e55** Differentiation between various Chondroitin sulfate formulations in symptomatic knee osteoarthritis

 J Y Reginster